Pharma BD Deal Intelligence
Sanofi acquired Principia Biopharma for $3.7B for BTK inhibitor.
Sanofi received an FDA Complete Response Letter for tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS) on December 24, 2025; the…
Sanofi completed the $3.68 billion acquisition of Principia Biopharma, gaining full control of tolebrutinib and additional BTK inhibitors to strengthen its…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi acquired Principia Biopharma in an all-cash tender offer at $100/share (~$3.68 billion), announced August 17, 2020 and completed September 28, 2020, to build out its autoimmune and neurology pipeline around Principia's oral BTK-inhibitor platform. The two lead assets diverged post-close: rilzabrutinib, a reversible covalent BTK inhibitor, won FDA approval as WAYRILZ on August 29, 2025 for persistent or chronic immune thrombocytopenia (ITP) -- the first BTK inhibitor approved for ITP, with subsequent EU and UAE approvals. Tolebrutinib, the brain-penetrant BTK inhibitor positioned as the deal's headline multiple sclerosis asset, received an FDA Complete Response Letter on December 24, 2025 for non-relapsing secondary progressive MS (nrSPMS); Sanofi stated it would work with the FDA on a path forward.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Principia Biopharma (this deal) | 2020 | $3.7B | 41 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2020 deals · Sanofi SA deals · Immunology deals